Carboplatin - Generic Drug Details
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What are the generic drug sources for carboplatin and what is the scope of patent protection?
Carboplatin
is the generic ingredient in two branded drugs marketed by Cipla Ltd, Fresenius Kabi Usa, Hikma, Hospira, Mylan Labs Ltd, Pliva, Sandoz, Watson Labs Teva, Corden Pharma, Accord Hlthcare, Actavis Totowa, Akorn, Eugia Pharma, Gland Pharma Ltd, Meitheal, Mylan Institutional, Novast Labs, Pharmachemie Bv, Pliva Lachema, Sandoz Inc, Sun Pharm, Teva Parenteral, Teva Pharms Usa, Teyro Labs, and Cordenpharma, and is included in thirty-five NDAs. Additional information is available in the individual branded drug profile pages.There are eighteen drug master file entries for carboplatin. Seven suppliers are listed for this compound.
Summary for carboplatin
| US Patents: | 0 |
| Tradenames: | 2 |
| Applicants: | 25 |
| NDAs: | 35 |
| Drug Master File Entries: | 18 |
| Finished Product Suppliers / Packagers: | 7 |
| Raw Ingredient (Bulk) Api Vendors: | 26 |
| Clinical Trials: | 2,840 |
| Patent Applications: | 161 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price trends for carboplatin |
| What excipients (inactive ingredients) are in carboplatin? | carboplatin excipients list |
| DailyMed Link: | carboplatin at DailyMed |
Recent Clinical Trials for carboplatin
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Shanghai Henlius Biotech | Phase 2 |
| Kamya Sankar | Phase 2 |
| University of Michigan | Phase 2 |
Pharmacology for carboplatin
| Drug Class | Platinum-based Drug |
Medical Subject Heading (MeSH) Categories for carboplatin
US Patents and Regulatory Information for carboplatin
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan Labs Ltd | CARBOPLATIN | carboplatin | INJECTABLE;INJECTION | 091510-002 | May 29, 2012 | DISCN | No | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| Fresenius Kabi Usa | CARBOPLATIN | carboplatin | INJECTABLE;INTRAVENOUS | 077247-001 | Oct 21, 2004 | DISCN | No | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| Gland Pharma Ltd | CARBOPLATIN | carboplatin | INJECTABLE;INTRAVENOUS | 207324-004 | Feb 15, 2017 | AP | RX | No | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | |||
| Pharmachemie Bv | CARBOPLATIN | carboplatin | INJECTABLE;INTRAVENOUS | 077269-001 | Oct 14, 2004 | AP | RX | No | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for carboplatin
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Cordenpharma | PARAPLATIN | carboplatin | INJECTABLE;INTRAVENOUS | 020452-004 | Jan 15, 2004 | See Plans and Pricing | See Plans and Pricing |
| Corden Pharma | PARAPLATIN | carboplatin | INJECTABLE;INJECTION | 019880-001 | Mar 3, 1989 | See Plans and Pricing | See Plans and Pricing |
| Cordenpharma | PARAPLATIN | carboplatin | INJECTABLE;INTRAVENOUS | 020452-001 | Jul 14, 2003 | See Plans and Pricing | See Plans and Pricing |
| Cordenpharma | PARAPLATIN | carboplatin | INJECTABLE;INTRAVENOUS | 020452-003 | Jul 14, 2003 | See Plans and Pricing | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2022 - 2023
NCE-1 Patent Challenge Dates 2022 - 2023
ClinicalTrialExchange - Connecting volunteers and trials
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2022, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
